The European Medicines Agency will review drugs similar to Vioxx after Merck's withdrawal due to increased stroke and heart attack risks.
Pfizer's Celebrex is deemed safer, while Bextra poses potential dangers.
Lawsuits against Merck in Canada and the US are mounting, with estimates of up to $12 billion in costs.
Vioxx's withdrawal led to a significant drop in Merck's earnings, sparking a flurry of lawsuits.
Concerns over cardiovascular risks associated with Vioxx have prompted a wave of legal actions, with potential class-action suits on the horizon.
